Patents by Inventor Zakaryae Fathi

Zakaryae Fathi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240091555
    Abstract: Methods of treating a subject are provided, involving providing a first region of biological material coupled to the subject; initiating a change in a cellular environment of the cells in the first region; and due to a change in biological or chemical activity of the cells in the first region, inducing a biological change in a second region inside the subject, along with various biophoton collectors and biophoton bypasses useful for implementing a variety of the method embodiments.
    Type: Application
    Filed: October 27, 2023
    Publication date: March 21, 2024
    Inventors: FREDERIC A. BOURKE, JR., HAROLD WALDER, ZAKARYAE FATHI, WAYNE F. BEYER, JR., RONALD A. RUDDER
  • Patent number: 11901331
    Abstract: A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.
    Type: Grant
    Filed: January 6, 2022
    Date of Patent: February 13, 2024
    Assignee: IMMUNOLIGHT, LLC
    Inventors: Zakaryae Fathi, James Clayton, Harold Walder, Frederic A. Bourke, Jr.
  • Publication number: 20240042233
    Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.
    Type: Application
    Filed: July 27, 2023
    Publication date: February 8, 2024
    Applicants: Immunolight, LLC, DUKE UNIVERSITY
    Inventors: Harold WALDER, Frederic A. BOURKE, JR., Zakaryae FATHI, Wayne F. BEYER, JR., Mark DEWHIRST, Mark OLDHAM, Justus ADAMSON, Michael NOLAN
  • Patent number: 11865359
    Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: January 9, 2024
    Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer, Jr., Mark Dewhirst, Mark Oldham, Justus Adamson, Michael Nolan
  • Patent number: 11833367
    Abstract: Methods of treating a subject are provided, involving providing a first region of biological material coupled to the subject; initiating a change in a cellular environment of the cells in the first region; and due to a change in biological or chemical activity of the cells in the first region, inducing a biological change in a second region inside the subject, along with various biophoton collectors and biophoton bypasses useful for implementing a variety of the method embodiments.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: December 5, 2023
    Inventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Wayne F. Beyer, Jr., Ronald A. Rudder
  • Publication number: 20230338539
    Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.
    Type: Application
    Filed: June 7, 2021
    Publication date: October 26, 2023
    Inventors: Frederic A. BOURKE, Jr., Harold WALDER, Zakaryae FATHI
  • Patent number: 11786595
    Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: October 17, 2023
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark Oldham, Justus Adamson, Mark W. Dewhirst, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer, Jr.
  • Publication number: 20230292413
    Abstract: Methods and systems for producing a change in a medium. A first method and system (1) place in a vicinity of the medium at least one upconverter including a gas for plasma ignition, with the upconverter being configured, upon exposure to initiation energy, to generate light for emission into the medium, and (2) apply the initiation energy from an energy source including the first wavelength ?1 to the medium, wherein the emitted light directly or indirectly produces the change in the medium. A second method and system (1) place in a vicinity of the medium an agent receptive to microwave radiation or radiofrequency radiation, and (2) apply as an initiation energy the microwave radiation or radiofrequency radiation by which the agent directly or indirectly generates emitted light in the infrared, visible, or ultraviolet range to produce at least one of physical and biological changes in the medium.
    Type: Application
    Filed: January 25, 2023
    Publication date: September 14, 2023
    Applicants: Immunolight, LLC, Duke University
    Inventors: Frederic A. BOURKE, JR., Zakaryae FATHI, Ian Nicholas STANTON, Michael J. THERIEN, Paul Rath STAUFFER, Paolo MACCARINI, Katherine Sarah HANSEN, Diane Renee FELS, Cory Robert WYATT
  • Publication number: 20230191747
    Abstract: A method of and system for adhesive bonding by a) providing a polymerizable adhesive composition on a surface of an element to be bonded to form an assembly; b) irradiating the assembly with radiation at a first wavelength capable of vulcanization of bonds in the polymerizable adhesive composition by activation of sulfur-containing compound with at least one selected from x-ray, e-beam, visible, or infrared light to thereby generate ultraviolet light in the polymerizable adhesive composition; and c) adhesively joining two or more components together by way of the polymerizable adhesive composition, and a curable polymer for use therein.
    Type: Application
    Filed: February 23, 2023
    Publication date: June 22, 2023
    Applicant: Immunolight, LLC
    Inventors: Zakaryae FATHI, Frederic A. BOURKE, JR., Harold WALDER
  • Patent number: 11678682
    Abstract: A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR2) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: June 20, 2023
    Assignee: IMMUNOLIGHT, LLC
    Inventors: Frederic A. Bourke, Jr., Zakaryae Fathi, Harold Walder, Wayne F. Beyer, Jr.
  • Patent number: 11648750
    Abstract: A method of and system for adhesive bonding by a) providing a polymerizable adhesive composition on a surface of an element to be bonded to form an assembly; b) irradiating the assembly with radiation at a first wavelength capable of vulcanization of bonds in the polymerizable adhesive composition by activation of sulfur-containing compound with at least one selected from x-ray, e-beam, visible, or infrared light to thereby generate ultraviolet light in the polymerizable adhesive composition; and c) adhesively joining two or more components together by way of the polymerizable adhesive composition, and a curable polymer for use therein.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: May 16, 2023
    Assignee: IMMUNOLIGHT, LLC
    Inventors: Zakaryae Fathi, Frederic A. Bourke, Jr., Harold Walder
  • Publication number: 20230109074
    Abstract: A pharmaceutical composition for modifying a target structure, which includes at least one agent selected from the group consisting of energy modulation agents, plasmonics-active agents and combinations thereof; the energy modulation agents, when present, including one or more light emitters capable of emitting at least two different wavelengths of light, each wavelength of light associated with a different biological response, and the at least two different wavelengths capable of activating different biological responses; and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 28, 2022
    Publication date: April 6, 2023
    Applicant: IMMUNOLIGHT, LLC
    Inventors: Frederic A. BOURKE, JR., Zakaryae FATHI, Harold WALDER
  • Patent number: 11589432
    Abstract: Methods and systems for producing a change in a medium. A first method and system (1) place in a vicinity of the medium at least one upconverter including a gas for plasma ignition, with the upconverter being configured, upon exposure to initiation energy, to generate light for emission into the medium, and (2) apply the initiation energy from an energy source including the first wavelength ?1 to the medium, wherein the emitted light directly or indirectly produces the change in the medium. A second method and system (1) place in a vicinity of the medium an agent receptive to microwave radiation or radiofrequency radiation, and (2) apply as an initiation energy the microwave radiation or radiofrequency radiation by which the agent directly or indirectly generates emitted light in the infrared, visible, or ultraviolet range to produce at least one of physical and biological changes in the medium.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: February 21, 2023
    Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Frederic A. Bourke, Jr., Zakaryae Fathi, Ian Nicholas Stanton, Michael J. Therien, Paul Rath Stauffer, Paolo Maccarini, Katherine Sarah Hansen, Diane Renee Fels, Cory Robert Wyatt
  • Patent number: 11577092
    Abstract: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: February 14, 2023
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne Beyer, Mark Oldham, Justus Adamson, Paul Yoon
  • Patent number: 11571587
    Abstract: A method for treating a disease, disorder, or condition in a subject in need thereof, by administering either or both of (i) at least one photoactivatable pharmaceutical agent, or (ii) a first plurality of energy-emitting particles, into the subject in a region of the disease, disorder, or condition, whereby the administering is performed through inhalation; and applying an applied electromagnetic energy to the subject, wherein the applied electromagnetic energy directly or indirectly activates the at least one photoactivatable pharmaceutical agent, when present, and wherein when the first plurality of energy-emitting particles is present, the first plurality of energy-emitting particles absorbs the applied energy and emits an emitted electromagnetic energy, wherein the emitted electromagnetic energy interacts directly with the region of the disease, disorder, or condition or activates the at least one photoactivatable pharmaceutical agent.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: February 7, 2023
    Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert
  • Patent number: 11534622
    Abstract: Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: December 27, 2022
    Assignee: IMMUNOLIGHT, LLC
    Inventors: Frederic A. Bourke, Jr., Zakaryae Fathi, Harold Walder
  • Patent number: 11476222
    Abstract: A curable resin or adhesive composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and at least one energy converting material, preferably a phosphor, capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: October 18, 2022
    Assignee: IMMUNOLIGHT, LLC
    Inventors: Zakaryae Fathi, James Clayton, Harold Walder, Frederic A. Bourke, Jr.
  • Publication number: 20220315809
    Abstract: An emission enhancement structure having at least one energy augmentation structure; and an energy converter capable of receiving energy from an energy source, converting the energy and emitting therefrom a light of a different energy than the received energy. The energy converter is disposed in a vicinity of the at least one energy augmentation structure such that the emitted light is emitted with an intensity larger than if the converter were remote from the at least one energy augmentation structure. Also described are various uses for the energy emitters, energy augmentation structures and energy collectors in a wide array of fields, including various adhesives applications.
    Type: Application
    Filed: February 27, 2020
    Publication date: October 6, 2022
    Applicant: IMMUNOLIGHT, LLC
    Inventors: Frederic A. BOURKE, JR., Harold WALDER, Zakaryae FATHI, Wayne F. BEYER, Ronald A. RUDDER, Joseph H. SIMMONS
  • Publication number: 20220275914
    Abstract: An emission enhancement structure having at least one energy augmentation structure; and an energy converter capable of receiving energy from an energy source, converting the energy and emitting therefrom a light of a different energy than the received energy. The energy converter is disposed in a vicinity of the at least one energy augmentation structure such that the emitted light is emitted with an intensity larger than if the converter were remote from the at least one energy augmentation structure. Also described are various uses for the energy emitters, energy augmentation structures and energy collectors in a wide array of fields, such as color enhancement, and color enhancement structures containing the same.
    Type: Application
    Filed: January 30, 2020
    Publication date: September 1, 2022
    Applicant: IMMUNOLIGHT, LLC
    Inventors: Frederic A. BOURKE, Jr., Harold WALDER, Zakaryae FATHI, Wayne F. BEYER, Ronald A. RUDDER, Joseph H. SIMMONS
  • Publication number: 20220226666
    Abstract: A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body; infusing the diseased site with a photoactivatable drug; applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume, wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 21, 2022
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, JR., Harold Walder, Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada